This report discusses the case of an 80-year-old female presenting with non-specific gastrointestinal symptoms and who was ultimately diagnosed as having metastatic melanoma of the jejunum. Notably, on admission, the patient had failed to report a past medical history of melanoma on her back a few years prior, and this significantly impacted the diagnostic process. This case highlights the challenges in diagnosing metastatic melanoma. It adds to the literature by underscoring the rarity and diagnostic complexity of this condition, which in this particular case presented as a jejunal mass.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556734 | PMC |
| http://dx.doi.org/10.7759/cureus.71373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Nat Med
January 2025
BioNTech US, Cambridge, MA, USA.
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy.
View Article and Find Full Text PDFCMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.
Cancer Immunol Immunother
January 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), Medical Faculty Heidelberg, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.
Cytomegalovirus (CMV) infection or reactivation in immune-compromised individuals can lead to a wide range of severe complications including hepatitis. However, its relation with immune checkpoint inhibitors (ICIs) induced hepatitis (ICI-hepatitis) and tumor responses in advanced melanoma patients remains unclear. Hundred and ninety metastatic cutaneous melanoma patients (mCM) who received ICI treatment, with CMV IgG or IgM information available at baseline, were included in the study (Cohort 1).
View Article and Find Full Text PDFFeasibility and impact of sentinel lymph node biopsy in patients affected by ano-rectal melanoma.
Tech Coloproctol
January 2025
Department of Surgical Sciences, University of Turin, Turin, Italy.
Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.
View Article and Find Full Text PDFDesign and Synthesis of Triazine-Based Hydrogel for Combined Targeted Doxorubicin Delivery and PI3K Inhibition.
ACS Biomater Sci Eng
January 2025
School of Biological Sciences, Indian Association for the Cultivation of Science, 2A & 2B Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India.
Melanoma, an aggressive skin cancer originating from melanocytes, presents substantial challenges due to its high metastatic potential and resistance to conventional therapies. Hydrogels, 3D networks of hydrophilic polymers with high water-retention capacities, offer significant promise for controlled drug delivery applications. In this study, we report the synthesis and characterization of hydrogelators based on the triazine molecular scaffold, which self-assemble into fibrous networks conducive to hydrogel formation.
View Article and Find Full Text PDFIs S100B protein useful in the follow up of non-metastatic cutaneous melanoma patients? A real-world cohort study.
Actas Dermosifiliogr
December 2024
Dermatology Department, Hospital Universitario de la Princesa, Madrid, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!